Navigation Links
China-Biotics to Report Fiscal Year 2011 Second Quarter Financial Results on November 9
Date:10/26/2010

SHANGHAI, Oct. 26 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics", the "Company") (Nasdaq: CHBT), the leading developer, manufacturer and distributor of probiotics products in China, today announced it will host a conference call at 8:00 a.m. Eastern Standard Time / 9:00 p.m. Beijing Time on Tuesday, November 9, 2010, to discuss the fiscal year 2011 second quarter and six months financial results for the period ended September 30, 2010.

The telephone numbers for the conference call are (866) 383-7998 (U.S.) or (617) 597-5329 (International), passcode: 45985589.  A live web cast of the call will also be available on the investor relations section of the Company's website www.chn-biotics.com. To listen to the web cast, please visit the site at least 10 minutes early to register, download and install any necessary audio software.

The replay of the web cast will be archived on the website, and investors will be able to access the recording of the conference call until midnight EST on November 16, 2010 by calling (888) 286-8010 (U.S.) or (617) 801-6888 (International) and entering passcode: 21680945.

About China-BioticsChina-Biotics, Inc. ("China-Biotics" or "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering (Shanghai) Co. Ltd., the Company develops and produces its proprietary product portfolio. Currently, the retail products are sold OTC mainly through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. The Company also sells bulk products to institutional customers such as dairy and animal feed producers, as
'/>"/>

SOURCE China-Biotics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. China-Biotics Hosted its First Investor Day Event
2. China-Biotics Ranked Number 62 on FORTUNES 100 Fastest-Growing Companies List
3. China-Biotics to Report Fiscal Year 2011 First Quarter Financial Results on August 9
4. China-Biotics Provides Further Updates on Qingpu New Facility
5. China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010
6. China-Biotics to Report Fourth Quarter and Fiscal Year 2010 Financial Results on June 11
7. China-Biotics to Present at Bank of America Merrill Lynch Healthcare Event on June 22
8. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
9. China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor
10. China-Biotics, Inc. Inaugurated the Commercial Production of its New Production Facility
11. China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... September 1, 2010, ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... Primary Endpoint in Second Phase III Trial in VMA, Confirms... -- LEUVEN, Belgium, September 1, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... that a new market research report is available ... - Pipeline Assessment and Market Forecasts to 2017 ... Women,s Infertility - Pipeline Assessment and Market ... industry analysis specialist, has released its new report, ...
Cached Biology Technology:EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 2EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 3EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 4EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 5EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 6EUSA Pharma Announces the Appointment of Stephen A. Stamp to its Board of Directors 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 2Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 3Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 4Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 5Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 6Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 8Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 9Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 10Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 11Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 6
(Date:7/9/2014)... ranges in which animals can be found, concern mounts ... an increased range for a host mean new territory ... a team of UC Santa Barbara scientists, including parasitologists ... in the Journal of Biogeography , Hechinger, Kuris ... may happen: Hosts may actually lose their parasites when ...
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat ... population declines of amphibians, bats, corals, bees and ... Florida published in the prestigious journal Nature ... immunological resistance to a deadly chytrid fungus implicated ... resistance is important because it is the basis ...
(Date:7/9/2014)... children with traumatic injuries have identified an immune ... develop a hospital-acquired infection. The study, led by ... in June in the journal Shock , ... lead to the clinical implementation of quick-turnaround immune ... immune system damage following critical illness or injury ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... Global Information Inc is pleased to offer attendees their ... the world. Early Bird registration prices end as early ... to 15%. (Photo: http://photos.prnewswire.com/prnh/20120918/CG76491 ) ... | San Francisco, California CHI,s High-Content Analysis ...
... ARLINGTON, Va.Dr. John P. Holdren, White House Office of ... powerful roster of military and government leaders at the ... Conference and ASNE Expo, officials announced Sept. 18. ... S&T and co-chair of the President,s Council of Advisors ...
... is one of the most serious complications related to ... grown in Peru and Chile is a relative of ... The maize is rich in anthocyanins (also known as ... from the Department of Food and Nutrition and Department ...
Cached Biology News:International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 2International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 3International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering 4ONR lines up speakers and technologies for 2012 Naval Conference 2Purple corn compound may aid in developing future treatments for Type 2 diabetes, kidney disease 2
... cell with multi-casting chamber is used for handcasting ... format handcast (8.3 x 7.3 cm) or precast ... 3.4-4.4 L of buffer and includes an electrophoresis ... an external refrigerated circulator (not included), lid with ...
...
... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
...
Biology Products: